The estimated Net Worth of Jarrett Disbrow is at least $1.9 Milión dollars as of 6 March 2018. Mr. Disbrow owns over 226,105 units of Aytu BioPharma Inc stock worth over $1,103,120 and over the last 9 years he sold AYTU stock worth over $0. In addition, he makes $793,413 as Chief Operating Officer at Aytu BioPharma Inc.
Jarrett has made over 5 trades of the Aytu BioPharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 226,105 units of AYTU stock worth $101,747 on 6 March 2018.
The largest trade he's ever made was buying 250,000 units of Aytu BioPharma Inc stock on 6 May 2016 worth over $100,000. On average, Jarrett trades about 75,701 units every 60 days since 2015. As of 6 March 2018 he still owns at least 439,490 units of Aytu BioPharma Inc stock.
You can see the complete history of Mr. Disbrow stock trades at the bottom of the page.
Jarrett T. (Josh) Disbrow is the Chief Operating Officer of the Company. Mr. Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix Pharmaceuticals from November 2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals’ acquisition in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Prior to founding Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing. Mr. Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. Mr. Disbrow served on our Board of Directors from April 2015 to July 2016.
As the Chief Operating Officer of Aytu BioPharma Inc, the total compensation of Jarrett Disbrow at Aytu BioPharma Inc is $793,413. There are 2 executives at Aytu BioPharma Inc getting paid more, with Joshua Disbrow having the highest compensation of $1,043,700.
Jarrett Disbrow is 44, he's been the Chief Operating Officer of Aytu BioPharma Inc since 2016. There are 9 older and 1 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.
Jarrett's mailing address filed with the SEC is C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.
Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery a Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
Aytu BioPharma Inc executives and other stock owners filed with the SEC include: